达拉图马布用于CD20-CD38+复发性/反射性扩散型大B细胞淋巴瘤
ZeTong Hong1, ZhaoYang Hong2, YaXian Ma1
1Department of Hematology, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Journal of cellular and molecular medicine
|October 17, 2025
概括
达拉图马布为复发性/耐药性扩散性大B细胞淋巴瘤 (R/R DLBCL) 患者提供了有前途的治疗方法,患者的CD20-CD38+表达,表现出良好的缓解率,并有助于CAR-T治疗过渡.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 复发性/不耐药的扩散性大B细胞淋巴瘤 (R/R DLBCL) 患者在接受rituximab治疗后经常表现出减少的CD20表达.
- 针对性的治疗替代对于R/R DLBCL治疗至关重要.
- 在R/R DLBCL中CD38表达值得研究替代治疗点.
研究的目的:
- 评估Daratumumab作为CD20-CD38+R/RDLBCL患者的单疗法或组合化疗.
- 为了评估Daratumumab在以前的CD20向治疗失败的患者中的疗效.
- 确定达拉图穆马布对随后的CAR-T (化学抗原受体T细胞免疫疗法) 的辅助作用.
主要方法:
- 对四名CD20-CD38+ R/R DLBCL患者的回顾性分析,这些患者接受了基于达拉图姆的组合化疗.
- 对符合条件的患者进行后续的CAR-T治疗.
- 在小鼠中构建全移植瘤模型以进行评估.
主要成果:
- 四名患者实现了不同程度的缓解:2例完全缓解 (CR),1例部分缓解 (PR) 和1例稳定疾病 (SD).
- 一年整体存活率为75%,一年无进展存活率为50%,平均存活率为12个月.
- 副作用是中度和可逆的;两名患者成功过渡到CAR-T治疗,患有可管理的1级细胞因子释放综合征 (CRS).
结论:
- 达拉图穆马布联合治疗显示出治疗CD20-CD38+ R/R DLBCL的显著潜力.
- 达拉图穆马布作为后续CAR-T治疗的可行的桥梁疗法.
- 这种方法为R/R DLBCL患者提供了有前途的替代方案,CD20表达减少.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)

